BioSpace News Archive

Drug Development

A 2nd Patient Death Reported in Novartis’ Gene Therapy Trial

Just as Novartis and AveXis’ gene therapy, Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy (SMA) is progressing toward approval, a second patient death was reported.

April 22, 2019
·
3 min read
·
Mark Terry
Business

CAR-T Drugmaker Poseida Snags $142 Million in Financing Led by Novartis

Swiss pharma giant Novartis supported the company’s Series C financing round with a $75 million equity investment.

April 22, 2019
·
2 min read
·
Alex Keown
FDA

Merck’s Keytruda Racks up Another Approval in Advanced Renal Cell Carcinoma

Renal cell carcinoma is also called renal cell cancer or renal cell adenocarcinoma. Approximately 90% of all kidney cancers are renal cell carcinomas.

April 22, 2019
·
3 min read
·
Mark Terry
Drug Development

Lilly’s Taltz Shows Promise in Spondyloarthritis Trial

Eli Lilly and Company announced results from its COAST-X Phase III clinical trial of Taltz (ixekizumab) in non-radiographic axial spondyloarthritis (nr-axSpA) in patients who had no previous disease-modifying anti-rheumatic drug (bDMARD) treatment.

April 22, 2019
·
3 min read
·
Mark Terry
Business

MD Anderson Ousts Three Scientists Over Intellectual Property Theft Concerns

Steps have been taken to safeguard the cancer center, including development of a cutting-edge approach to Enterprise Risk Management.

April 22, 2019
·
3 min read
·
Alex Keown
Are You the Leadership Problem? How to Improve Your Leadership Skills to Get the Results You Want

Over the last few years, large organizations in the life sciences and pharmaceutical industries such as Theranos and Turning Pharmaceuticals, have been marred in allegations of fraud and other illegal activities.

April 22, 2019
·
3 min read
·
Porschia Parker
Policy

New insight into how obesity, insulin resistance can impair cognition

Obesity can break down our protective blood brain barrier resulting in problems with learning and memory, scientists report.

April 22, 2019
·
7 min read
FDA

FDA Approves Teva’s Generic Naloxone Opioid Overdose Drug

The FDA said the approval of Teva’s product is the first generic naloxone nasal spray for use in a community setting by individuals without medical training.

April 22, 2019
·
2 min read
·
Alex Keown
Business

Eli Lilly and Avidity Forge Agreement for Immunologic Candidates

The two companies will combine their expertise to drive new immunology candidates toward the clinic.

April 22, 2019
·
3 min read
·
Alex Keown
Job Trends

Company Growth, Ambition Drive Ultragenyx’s Continued Success

Two years after its acquisition of Dimension Therapeutics, Bay Area-based Ultragenyx Pharmaceutical, Inc. continues to see success in its clinical programs for the company’s adeno-associated virus (AAV) gene therapy treatments and in its overall growth.

April 22, 2019
·
3 min read
·
Alex Keown